Global acetazolamide market is driven by increasing prevalence of glaucoma. Acetazolamide is a carbonic anhydrase inhibitor drug primarily used for the treatment of glaucoma. It reduces the amount of fluid in the eye by inhibiting the carbonic anhydrase enzyme and lowering intraocular pressure. Acetazolamide comes in tablet, capsule, and intravenous forms and is prescribed after the initial treatment with eye drops fails to adequately lower pressure or if surgery is not a viable option.

The Global Acetazolamide Market Share was estimated to be US$ 303.03 Bn in 2024 and is anticipated to register a CAGR of 13% during the forecast period of 2024 to 2030.

Key Takeaways

Key players operating in the acetazolamide market are Merck KgaA, QIAGEN NV, Illumina Inc., Micronit BV, PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx Biotech Group, and Danaher Corporation (Cepheid), among others. Acetazolamide being the only effective medication has led to increasing demand for the drug. The key market players are focused on expansions, collaborations and new product launches to enhance their global footprint and better serve the demand from medical professionals and glaucoma patients globally.

Growing demand in market:

The growing prevalence of glaucoma across the world is the major factor driving the growth of the global acetazolamide market. As per the estimates of World Health Organization (WHO), over 3 million people globally are blind due to glaucoma. It has been reported that globally over 60 million people suffer from primary angle-closure glaucoma with women being three times more affected than men.

Global expansion of market:

The increasing collaborations between the key market players to expand geographical presence fuels the growth of the acetazolamide market globally. The rising investments by the government and private organizations in development of novel drugs for treatment of glaucoma further support the market growth. Additionally, the growing awareness regarding early glaucoma diagnosis supplements the increasing demand of acetazolamide over the forecast period.

Market drivers:

One of the key drivers for the acetazolamide market is increasing aging population worldwide. The condition is more common in geriatric patients and the proportion of geriatric population is rising rapidly globally. As per the United Nations’ World Population Ageing report, the number of people aged 65 years or over is projected to grow from 703 million in 2019 to 1.5 billion in 2050. The rising geriatric populace susceptible to developing glaucoma will augment the demand of acetazolamide over coming years.

The global security environment has significantly deteriorated in 2022 with the ongoing conflict in Ukraine intensifying geopolitical tensions. This has impacted several industries globally as supply chains have been disrupted due to sanctions imposed on Russia. The acetazolamide market is also expected to be affected in the short to medium term. Countries in Europe which earlier imported raw materials and intermediates from Russia will now need to find new reliable suppliers. While countries like India, China and South America can help plug supply gaps, it will take time to establish long term supply contracts and stabilize prices.

Geopolitical risks will remain elevated for the foreseeable future as major powers continue to spar over trade, technology and strategic influence. The acetazolamide market will see higher input costs and demand fluctuations owing to geopolitical developments in key exporting and importing regions. Companies need to closely monitor changes in trade policies and diversify their supplier networks across multiple regions to reduce vulnerabilities from concentration risks. Stockpiling of critical raw materials may also help mitigate shortages during times of conflict or sanctions. Collaborations in research & development can further aid in indigenization of technology and independence from politically unstable regions.

In terms of value, North America is currently the largest market for acetazolamide, estimated at over 35% share of the global total. This is attributed to rising incidence of glaucoma and a well-developed pharmaceutical sector in the US and Canada supported by favorable reimbursement policies. However, going forward the Asia Pacific region excluding Japan is poised to be the fastest growing regional market, expected to expand at a CAGR of around 15% during the forecast period. Rapid economic development, rising medical expenditures, growing geriatric population base susceptible to ophthalmic conditions are driving demand growth in countries like China and India.

Get More Insights Here

https://www.newsanalyticspro.com/acetazolamide-market-size-share-growth-outlook-2023/